Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

Recursive Agents implements a three-phase iterative refinement architecture where LLM agents (instances of Classes) critique and improve their own outputs. Unlike single-pass systems, each agent ...

Abstract: To tackle the challenge of data diversity in sentiment analysis and improve the accuracy and generalization ability of sentiment analysis, this study first cleans, denoises, and standardizes ...

We’re racing towards a future in which devices will be able to read our thoughts. You see signs of it everywhere, from brain-computer interfaces to algorithms that detect emotions from facial scans.

Abstract: Traffic signal control (TSC) is a part of intelligent transportation systems to reduce traffic congestion and emissions. Recently, dynamic traffic signal control systems using artificial ...